BioSpace News Archive

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2022, after the close of the market on Thursday, May 5, 2022.

Virax Biolabs Group Limited (“Virax” or the “Company”) is pleased to announce the appointment of Jason D. Davis to the role of Chief Financial Officer, effective immediately.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), announced the publication of two manuscripts in Nature Communications on its product candidate UCART123, currently being evaluated in the Phase 1 dose-escalation trial AMELI-01 in patients with relapsed or refractory acute myeloid leukemia (r/r AML).

Integer Holdings Corporation, a leading medical device outsource manufacturer, announced results for the three months ended April 1, 2022.

Formosa Pharmaceuticals, Inc. (TWO.6838) and Aimmax Therapeutics, Inc. (United States) announced that results from a Phase 2 clinical study of APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), a novel formulation of the potent corticosteroid, clobetasol propionate, for the treatment of inflammation and pain after cataract surgery, will be presented at the 2022 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO).

Ardelyx, Inc. today announced that it will hold a conference call on Thursday May 5 at 4:30 pm Eastern Time to review first quarter 2022 financial results and provide a business overview.

Tryp Therapeutics , Inc. announced today that the first patient has been dosed in the Company’s Phase II clinical trial for its lead candidate, TRP-8802. In combination with psychotherapy, TRP-8802 is intended to serve as a potential treatment of Binge Eating Disorder (“BED”).

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced that the European Commission has granted marketing authorization to Kapruvia® for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients.

Sedana Medical AB announces that the first patient has been enrolled in the company’s US clinical studies.

Albany NY, United States: According to the report, the global digital dentistry materials & systems market was valued at US$ 2.9 Bn in 2020 and is projected to expand at a CAGR of 14.3% from 2021 to 2031.